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ADXS11-001 immunotherapy is a live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete a HPV-16-
E7 fusion protein targeting HPV transformed cells. The
Lm vector serves as its own adjuvant and infects antigen
presenting cells (APC) where it cross presents, stimulat-
ing MHC class I and II pathways resulting in specific
T-cell immunity to tumors. Here we describe final
12 month overall survival data associated with ADXS11-
001 administration in Lm-LLO-E7-015, a randomized P2
study conducted in India in 110 patients with recurrent
cervical cancer; previously treated with chemotherapy,
radiotherapy or both. Patients were randomized to either
1 cycle (3 doses) of ADXS11-001 at 1 x 109 cfu or 4
doses of ADXS11-001 at 1 x 109 cfu with cisplatin che-
motherapy. Naprosyn and oral promethazine were given
as premedications and a course of ampicillin was given
72 hours after infusion. Patients received CT scans at
baseline and 3, 6, 9, 12 and 18 months. The primary end-
point is overall survival. As of May 17, 2013, the trial has
completed enrollment and 110 patients received 264
doses of ADXS11-001. The percentage of patients at
12 months is 36% (39/110) and currently the 18 month
survival is 22% (16/73). The response rate was 11%
(6 CRs and 6 PR/110) with tumor responses observed in
both treatment arms. 33 additional patients had stable
disease > 3 months, for a disease control rate of 41%
(45/110). Activity was observed against all high risk HPV
strains detected. Two Grade 3 serious adverse events and
104 mild-moderate adverse events possibly related/
related to ADXS11-001 treatment have been reported in
41% (45/110) of patients. The non-serious adverse events
consisted predominately of transient, non-cumulative flu-
like symptoms associated with infusion that either self-
resolved or responded to symptomatic treatment.
ADXS11-001 can be safely administered to patients with
advanced cancer alone and in combination with che-
motherapy. ADXS11-001 is well tolerated and presents a
predictable and manageable safety profile. The addition
of cisplatin to ADXS11-001 in this study did not signifi-
cantly improve tumor responses or overall survival.
Objective tumor responses included CR’s and apparent
prolonged survival with minimal adverse experiences.
Average duration of response in both treatment groups
was 10.5 months. The 36% 12 month survival and 11%
response rate observed in this recurrent disease setting is
encouraging and suggests that ADXS11-001 is an active
agent in recurrent cervical cancer. Final 18 month overall
survival will be presented at the meeting.
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